Why Phage Display
Transforming the Affinity Reagent Discovery Landscape
At Tango Biosciences, we understand that precision affinity reagents are critical to generate high-quality results. Shorten your reagent development time, save money, and gain confidence in the quality of your decision-driving data with our innovative phage display technology.
Unlike traditional antibody discovery methods that require animal immunization, our recombinant phage display solutions are sustainable and reliable. Going recombinant means you eliminate batch-to-batch variability and questions surrounding your data that could potentially send you down an unsuccessful research path.
The Avidimer Platform
Are you interested in developing bispecific or multimeric antibodies? Are you developing sandwich ELISA assays for lateral flow or other detection or diagnostic applications?
Tango Biosciences’ proprietary Avidimer platform offers an accelerated workflow for multimerized monobody, nanobody, and antibody discovery. This innovative technology is designed to identify a range of 5 to 15 two (or more)-site capable binders (multimers) as part of the affinity selection process. Our flexible linker solutions can adjust spacing and arrangement between Avidimers to optimize binding to your targets.
The Avidimer platform offers specific advantages over traditional monomeric phage display:
- Thousands of pair-wise combinations of monobodies, nanobodies, or antibodies are screened simultaneously for the fastest workflow
- Increased sensitivity and specificity of the resulting affinity reagents and binding assay
- Opportunities to identify weak to moderate binders to novel epitopes
The Avidimer platform is flexible to ensure the greatest chance of success for designer assay formats and multimeric binders.
Tech Note
Download this new tech note to learn how Avidimers accelerate sandwich assay development.